 |
7 Diseases |  |
0 Trials |
|
0 Trials |  |
50 News |  |
- | ONZETRA Xsail (sumatriptan intranasal) / Otsuka
Enrollment change: Study to Assess the Safety and Efficacy of ONZETRA (clinicaltrials.gov) - Jul 27, 2023
P3, N=159, Terminated, Sponsor: Currax Pharmaceuticals
N=314 --> 159
- | ONZETRA Xsail (sumatriptan intranasal) / Otsuka, Tosymra (intranasal sumatriptan) / Sawai Pharma, Neurelis, ZEMBRACE SymTouch (sumatriptan succinate) / Sawai Pharma
Journal: Comparison table: Triptans. (Pubmed Central) - Jun 6, 2023
N=314 --> 159 No abstract available
- | Journal: Drugs for migraine. (Pubmed Central) - Jun 6, 2023
No abstract available No abstract available
- ||||||||| ONZETRA Xsail (sumatriptan intranasal) / Otsuka
Trial completion date, Trial termination, Trial primary completion date: Study to Assess the Safety and Efficacy of ONZETRA (clinicaltrials.gov) - Jul 8, 2022
P3, N=314, Terminated, Sponsor: Currax Pharmaceuticals
No abstract available Trial completion date: Aug 2023 --> Jun 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2023 --> Jun 2022; eDiary data collected not sufficient to utilize in the analysis of protocol endpoints
- || sumatriptan succinate / Generic mfg.
Review, Journal: Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine. (Pubmed Central) - Apr 9, 2022
Based on the extant findings, harnessing novel delivery systems can improve the bioavailability of ST and enhance its effectiveness against migraine attacks. However, further clinical studies are needed to approve the safety and efficacy of employing such systems in humans.
- |||||| ONZETRA Xsail (sumatriptan intranasal) / Otsuka
Enrollment open, Trial completion date, Trial primary completion date: Study to Assess the Safety and Efficacy of ONZETRA (clinicaltrials.gov) - Mar 16, 2021
P3, N=420, Recruiting, Sponsor: Currax Pharmaceuticals
However, further clinical studies are needed to approve the safety and efficacy of employing such systems in humans. Active, not recruiting --> Recruiting | Trial completion date: Dec 2021 --> Aug 2023 | Trial primary completion date: Dec 2021 --> Aug 2023
- | Botox (onabotulinumtoxin A) / GSK, AbbVie
Journal: Drugs for Migraine. (Pubmed Central) - Jan 23, 2021
Active, not recruiting --> Recruiting | Trial completion date: Dec 2021 --> Aug 2023 | Trial primary completion date: Dec 2021 --> Aug 2023 No abstract available
- | Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly
Journal: Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine. (Pubmed Central) - Sep 16, 2020
No abstract available No abstract available
- || ONZETRA Xsail (sumatriptan intranasal) / Otsuka, sumatriptan succinate / Generic mfg.
Clinical, Journal: Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial. (Pubmed Central) - Aug 2, 2020
P3
Increased WPV with AVP-825 in the first 15 minutes likely reflects the earlier onset of treatment effects with the device compared to oral sumatriptan. LSMEMs show promise as a novel approach for assessing and comparing consistency of treatment response in migraine trials.
- |||| ONZETRA Xsail (sumatriptan intranasal) / Otsuka
Trial completion date, Trial primary completion date: Study to Assess the Safety and Efficacy of ONZETRA (clinicaltrials.gov) - Jan 22, 2020
P3, N=420, Active, not recruiting, Sponsor: Currax Pharmaceuticals
LSMEMs show promise as a novel approach for assessing and comparing consistency of treatment response in migraine trials. Trial completion date: Nov 2019 --> Dec 2021 | Trial primary completion date: Nov 2019 --> Dec 2021
- | Clinical, Review, Journal: Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. (Pubmed Central) - Jul 26, 2019
Through this review article, we want to drag the attention of the researchers working in this field towards the challenges and hurdles of practical applicability IN delivery of anti-AD drugs. Moreover, the attention towards the clinical studies will ease the approval process for the administration of anti-Alzheimer drugs via IN route.
- | ONZETRA Xsail (sumatriptan intranasal) / Otsuka
Enrollment closed: Study to Assess the Safety and Efficacy of ONZETRA (clinicaltrials.gov) - Jul 16, 2019
P3, N=420, Active, not recruiting, Sponsor: Avanir Pharmaceuticals
Moreover, the attention towards the clinical studies will ease the approval process for the administration of anti-Alzheimer drugs via IN route. Recruiting --> Active, not recruiting
- | OptiNose sumatriptan (sumatriptan intranasal) / Otsuka
Clinical, Journal: AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial. (Pubmed Central) - Mar 29, 2019
AVP-825 treatment led to more rapid early reductions in Overall Nausea rates during the first hour, reduced odds of nausea from 30 minutes to 2 hours following treatment and reduced risk of TEN compared to oral sumatriptan. These results highlight the importance of separately assessing TEN and Nausea Relief in acute treatment trials of migraine.
- |||||||||| ONZETRA Xsail (sumatriptan intranasal) / Otsuka
New P3 trial: Study to Assess the Safety and Efficacy of ONZETRA (clinicaltrials.gov) - Nov 9, 2017
P3, N=420, Recruiting, Sponsor: Avanir Pharmaceuticals
- ||||||| ONZETRA Xsail (sumatriptan intranasal) / Otsuka
Trial completion: COMPASS: Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura (clinicaltrials.gov) - Oct 22, 2014
P3, N=275, Completed, Sponsor: Optinose US Inc.
These results highlight the importance of separately assessing TEN and Nausea Relief in acute treatment trials of migraine. Active, not recruiting --> Completed
- ||||| ONZETRA Xsail (sumatriptan intranasal) / Otsuka
Enrollment closed: COMPASS: Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura (clinicaltrials.gov) - Sep 24, 2013
P3, N=240, Active, not recruiting, Sponsor: Optinose US Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| ONZETRA Xsail (sumatriptan intranasal) / Otsuka
New P3 trial: COMPASS: Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura (clinicaltrials.gov) - Aug 15, 2012
P3, N=240, Active, not recruiting, Sponsor: Optinose US Inc.
- ||||||| ONZETRA Xsail (sumatriptan intranasal) / Otsuka
Trial completion: Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine (clinicaltrials.gov) - Aug 5, 2012
P3, N=230, Completed, Sponsor: Optinose US Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- ONZETRA Xsail (sumatriptan intranasal) / Otsuka
Enrollment change: Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX (clinicaltrials.gov) - Feb 27, 2012
P1, N=20, Completed, Sponsor: Optinose US Inc.
Recruiting --> Completed N=25 --> 20
- | ONZETRA Xsail (sumatriptan intranasal) / Otsuka
Trial completion: Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX (clinicaltrials.gov) - Feb 27, 2012
P1, N=20, Completed, Sponsor: Optinose US Inc.
N=25 --> 20 Recruiting --> Completed
- | ONZETRA Xsail (sumatriptan intranasal) / Otsuka
New P1 trial: Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX (clinicaltrials.gov) - Jan 3, 2012
P1, N=20, Completed, Sponsor: Optinose US Inc.
- |||||||||| ONZETRA Xsail (sumatriptan intranasal) / Otsuka
New P3 trial: Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine (clinicaltrials.gov) - Oct 27, 2011
P3, N=230, Completed, Sponsor: Optinose US Inc.